Amgen Launches Long-Approved Humira Biosimilar Amjevita By PacConAdmin | January 30, 2023 Amgen finally launched Amjevita (adalimumab-atto) in the U.S. yesterday, releasing the first rival to AbbVie’s mega-blockbuster anti-inflammatory drug, Humira. Source: Drug Industry Daily Posted in Drug Industry Daily